Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer

Trial Profile

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2018

At a glance

  • Drugs U3 1402 (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 26 Sep 2018 Enrollment to Dose Escalation cohort 1 was completed in April 2018, as per trial design presented at the 19th World Conference on Lung Cancer.
    • 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.
    • 05 Jun 2018 Enrollment to cohort 1 began in January 2018 as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top